Streetbeat News

Analyst Ratings

SBUX

Recent options trading activity for Starbucks (NASDAQ:SBUX) shows a bearish sentiment among big-money investors, with 54% of trades being bearish. The options activity suggests a price range of $75 to $105 for Starbucks. Analysts have mixed ratings, with price targets ranging from $103 to $120.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 3:30 pm

KIM

Compass Point analyst Floris Van Dijkum maintains a Buy rating on Kimco Realty and raises the price target from $25 to $28.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:30 pm

ELV

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $600.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:29 pm

IVT

Compass Point analyst Floris Van Dijkum maintains a Neutral rating on InvenTrust Properties (NYSE:IVT) and raises the price target from $28 to $29.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:28 pm

ORCL

Oppenheimer analyst Brian Schwartz has maintained a 'Perform' rating on Oracle (NYSE:ORCL).

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:27 pm

FRT

Compass Point analyst Floris Van Dijkum maintains a Buy rating on Federal Realty Investment (NYSE:FRT) and raises the price target from $125 to $130.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:26 pm

CVS

Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health, maintaining a price target of $62.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:26 pm

BRX

Compass Point analyst Floris Van Dijkum maintains a Buy rating on Brixmor Property Group and raises the price target from $28 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:25 pm

CNC

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Centene (NYSE:CNC) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:24 pm

AVBP

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for ArriVent BioPharma (NASDAQ:AVBP) and increased the price target from $35 to $39.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:24 pm